Combined Phacoemulsification and Diode Laser Therapy in Chronic Angle Closure Glaucoma
NCT ID: NCT05576493
Last Updated: 2023-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
88 participants
INTERVENTIONAL
2022-08-11
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phaco-Trabeculotomy Vs Phaco-Trabeculectomy
NCT04683055
CPC in Adult Refractory Glaucoma
NCT04921098
Micropulse Transscleral Diode Laser Cyclophotocoagulation (MP-TSCPC) as a Treatment Modality for Glaucoma Patients
NCT05299281
SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients
NCT07152132
Cyclophotocoagulation in Primary Open Angle Glaucoma
NCT04430296
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A:phaco+MP-TSCPC
22 patients with primary angle closure glaucoma will undergo phacoemulsification and micropulse cyclophotocoagulation
phaco+MP-TSCPC
The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
B:phaco+TSCPC
22 patients with primary angle closure glaucoma will undergo phaco and transscleral cyclophotocoagulation
phaco+TSCPC
The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
C:phaco+endocyclophotocoagulation
22 patients with primary angle closure glaucoma will undergo phaco and endocyclophotocoagulation after cataract removal
phaco+endocyclophotocoagulation
phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
D:phaco GSL
22 patients with primary angle closure glaucoma will undergo phaco and goniosynechiolysis
phaco GSL
phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
phaco+MP-TSCPC
The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
phaco+TSCPC
The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
phaco+endocyclophotocoagulation
phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
phaco GSL
phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
chronic angle closure glaucoma
Exclusion Criteria
* Patients with previous filtering surgery or cycloablative procedure
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fayrouz Aboalazayem
lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Abdelrahman, PhD
Role: STUDY_CHAIR
kasr alainy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr Alainy
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-68-2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.